Lymphoma, B-Cell: all 1,415 studies
Page 8 of 15. Open to participants first (328), then studies with results posted, then the rest; newest registration first within each.
- Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's LymphomaActive, not recruitingNCT05618327Phase 1
- Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell MalignanciesTerminatedNCT05611853Phase 1/2
- STAY-STRONG Study of Exercise Training During ChemotherapyCompletedNCT05556239Not applicable
- Comparison of Clinical Outcomes Among Patients Treated With TisagenlecleucelCompletedNCT05541328
- A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell TransplantActive, not recruitingNCT05540340Phase 1
- Multidimensional Assessment of Quality of Life, Social and Professional Life and Care Utilization in Patients With Diffuse Large Cell B-cell Lymphoma Treated With CAR-T CellsStatus unknownNCT05532761
- A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP TherapyStatus unknownNCT05527912Phase 2
- Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid MalignanciesWithdrawnNCT05513612Phase 1
- Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity SyndromeCompletedNCT05510596Not applicable
- TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaActive, not recruitingNCT05507541Phase 2
- Study of Efficacy of BZ019 in Large B-cell LymphomaStatus unknownNCT05472610Phase 2
- Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell MalignanciesTerminatedNCT05453396Phase 2
- A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell LymphomaWithdrawnNCT05431179Phase 3
- A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin LymphomaActive, not recruitingNCT05421663Phase 1/2
- Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell LymphomaActive, not recruitingNCT05412290Phase 1
- Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular LymphomaActive, not recruitingNCT05410418Phase 2
- Study of PIT565 in Relapsed and/or Refractory B-cell MalignanciesActive, not recruitingNCT05397496Phase 1
- Natural Killer (NK) Cell Therapy for B-Cell MalignanciesStatus unknownNCT05379647Phase 1
- Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL)CompletedNCT05366257
- Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLLTerminatedNCT05360238Phase 1/2
- A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaTerminatedNCT05354362Phase 1
- Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT05338892
- GPL in Patients with Relapsed/refractory Diffuse Large B Cell LymphomaActive, not recruitingNCT05335018Phase 2
- Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's LymphomaCompletedNCT05322330Phase 2
- Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedNCT05319028Phase 2
- Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell LymphomaTerminatedNCT05318963Phase 1
- Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's LymphomaWithdrawnNCT05312476Phase 2
- Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid MalignanciesActive, not recruitingNCT05270057Phase 1
- Safety, Efficacy and Pharmacokinetics of XKDCT023 in DLBCLStatus unknownNCT05269914Not applicable
- Sepantronium Bromide for the Treatment of High-grade B-cell LymphomaActive, not recruitingNCT05263583Phase 2
- MargheRITA (Remote Intelligence for Therapeutic Adherence)CompletedNCT05260203Not applicable
- Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT05228249Phase 1
- Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post TransplantWithdrawnNCT05222438Phase 2
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaTerminatedNCT05219513Phase 1
- A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)Active, not recruitingNCT05210868Phase 1/2
- Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of EpcoritamabActive, not recruitingNCT05206357Phase 1
- Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell LymphomaActive, not recruitingNCT05202782Phase 2
- A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin LymphomaActive, not recruitingNCT05201248Phase 1/2
- A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell LymphomaStatus unknownNCT05200312Phase 2
- HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaCompletedNCT05190068Phase 1
- Mechanism of Resistance to GNC-038 in Relapsed and Refractory Diffuse Large B-cell LymphomaStatus unknownNCT05189782
- A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double ExpressionActive, not recruitingNCT05189197Phase 2
- Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin LymphomaStatus unknownNCT05164770Phase 3
- Long-term Registry of Patients Treated With Loncastuximab TesirineWithdrawnNCT05160064
- Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)Status unknownNCT05155839Phase 1
- A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's LymphomaCompletedNCT05149391Phase 1
- Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell LymphomaStatus unknownNCT05143112Phase 1/2
- Characterisation of TIM-3/Gal-9 Immune Checkpoints in Primary Central Nervous System Diffuse Large B Cell LymphomasCompletedNCT05133505
- CAR T Cell Therapy Related Cardiovascular OutcomesCompletedNCT05130489
- Combining Intratumoral Metabolic Heterogeneity and Dissemination Feature (Dmax) on 18F-FDG PET/CT Improves Prognosis Prediction in DLBCLCompletedNCT05113576
- PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell MalignanciesTerminatedNCT05107856Phase 1
- Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell LymphomaStatus unknownNCT05106946Phase 1
- Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell LymphomaStatus unknownNCT05106907Phase 1
- Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin LymphomaStatus unknownNCT05097443Phase 3
- CAR20.19.22 T-cells in Relapsed, Refractory B-cell MalignanciesTerminatedNCT05094206Phase 1
- Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T TherapyCompletedNCT05064787Not applicable
- Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBLStatus unknownNCT05050630Phase 2
- Study of Oral LOXO-338 in Patients With Advanced Blood CancersCompletedNCT05024045Phase 1
- Venetoclax Plus Inotuzumab for B-ALLActive, not recruitingNCT05016947Phase 1
- Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell LymphomaStatus unknownNCT05014100Phase 2
- Polatuzumab Vedotin in Patients With Relapsed and Refractory Diffuse Large B Cell LymphomaCompletedNCT05006534
- PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell MalignanciesStatus unknownNCT05003141Phase 1
- CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHLWithdrawnNCT04995536Phase 1
- A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin LymphomasTerminatedNCT04986865Phase 1
- A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)WithdrawnNCT04974996Phase 1
- A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)Active, not recruitingNCT04970901Phase 1
- A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Active, not recruitingNCT04965493Phase 3
- SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's LymphomaStatus unknownNCT04948788Phase 2
- Study for Late Assessment of the Safety and Efficacy of Biosimilar RituximabCompletedNCT04928573
- A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)Active, not recruitingNCT04914741Phase 1/2
- the Effect of Broken Ganoderma Lucidum Spore Powder on Quality of Life and Immune Function in Patients With Diffuse Large B-cell Lymphoma After ChemotherapyStatus unknownNCT04914143Not applicable
- Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T CellsActive, not recruitingNCT04911478
- Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's LymphomaStatus unknownNCT04897477Phase 1/2
- Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS StudyCompletedNCT04890236Early Phase 1
- Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHLStatus unknownNCT04887012Phase 1
- Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat LymphomaActive, not recruitingNCT04884035Phase 1
- Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell LymphomaWithdrawnNCT04882163Phase 1/2
- Immune Responses to COVID-19 Vaccination in Lymphoma PatientsCompletedNCT04858568
- RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid MalignanciesTerminatedNCT04844086Phase 1
- Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell LymphomaActive, not recruitingNCT04842877Phase 2
- A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell LymphomaStatus unknownNCT04827004Phase 2
- Gene Abnormalities and Prognosis in Diffuse Large B-cell LymphomaStatus unknownNCT04825899
- CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell LymphomaCompletedNCT04812691Phase 1
- Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic LeukemiaTerminatedNCT04806035Phase 1
- Secondary Prognostic Index in RefrActory LymphomaStatus unknownNCT04804865
- Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell CancersTerminatedNCT04804254Phase 1
- Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCLStatus unknownNCT04796857Phase 1/2
- a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell LymphomaStatus unknownNCT04782193Phase 1/2
- Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic MalignanciesCompletedNCT04748185
- Induced-T Cell Like NK Cells for B Cell MalignanciesStatus unknownNCT04747093Phase 1/2
- Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)SuspendedNCT04746131Phase 1
- A Phase 1 Study of ADI-001 in B Cell MalignanciesTerminatedNCT04735471Phase 1
- DLBCL Treatment in Children and AdolescentsCompletedNCT04726995
- Dual Target CAR-T Cells in B-cell LymphomaStatus unknownNCT04723914Phase 1/2
- Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaNo longer availableNCT04705454
- Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCLStatus unknownNCT04705129Phase 2
- Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHLActive, not recruitingNCT04697940Phase 1/2
- CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.SuspendedNCT04697290Early Phase 1
- Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCLCompletedNCT04697160
- A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's LymphomaCompletedNCT04696432Phase 1